Skip to main content
. 2019 Sep 12;48:332–340. doi: 10.1016/j.ebiom.2019.08.059

Fig. 4.

Fig. 4

A clinical radiomics nomogram.

A multivariate nomogram combining the Radiomics-T2FS prediction model with the AJCC clinical staging system is illustrated (a). The receiver operator characteristic (ROC) curve and the representative area under the curve (AUC), as well as the calibration curve, each at two  years, are shown (b,c). The Kaplan Meier survival curve for patients' overall survival displaying patient stratification by the proposed nomogram is depicted (d). Finally, decision durve analysis was performed comparing the net benefit by the Radiomics-T2FS nomogram with the AJCC clinical stage and tumor grading alone. The net benefit is calculated by subtracting the proportion of false-positive patients from the proportion of true-positive patients, weighted by the relative harm of a false-negative and false-positive result [28]. The threshold probability was calculated for death after five years. For reference, the two strategies “treat all” and “treat none” are displayed. A decision model shows a clinical benefit if the respective curve shows larger net benefit values than both reference strategies.

HHS Vulnerability Disclosure